Molecular characterization of human skin response to diphencyprone at peak and resolution phases: Therapeutic insights

Journal of Investigative Dermatology

Volumn 134, Issue 10, 2014, Pages 2531-2540

  Gulati, Nicholas ^a   Suárez Fariñas, Mayte ^a   Fuentes Duculan, Judilyn ^a   Gilleaudeau, Patricia ^a   Sullivan Whalen, Mary ^a   Correa Da Rosa, Joel ^a   Cueto, Inna ^a   Mitsui, Hiroshi ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; CD3 ANTIGEN; CHEMOKINE RECEPTOR CXCR1; CXCL9 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL LYSOSOME ASSOCIATED MEMBRANE PROTEIN; DIPHENCYPRONE; FLT3 LIGAND; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN P 15095; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 24; LANGERIN; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; STAT1 PROTEIN; CYCLOPROPANE DERIVATIVE; CYTOKINE; HAPTEN; IMMUNOLOGIC FACTOR; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN;

ARTICLE; CELL KINETICS; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DERMATITIS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LYMPHOCYTIC INFILTRATION; MYELOID DENDRITIC CELL; PLACEBO EFFECT; PRIORITY JOURNAL; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; SKIN BIOPSY; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; ADULT; BIOPSY; DOSE RESPONSE; DRUG EFFECTS; FEMALE; LANGERHANS CELL; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN; T LYMPHOCYTE;

ADULT; BIOPSY; CYCLOPROPANES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HAPTENS; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LANGERHANS CELLS; MALE; MIDDLE AGED; SKIN; T-LYMPHOCYTES;

EID: 84922393839     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.196     Document Type: Article

References (25)

1. Antonicelli F, Lorin J, Kurdykowski S et al. (2011) CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. Br J Dermatol 164: 720-8
2. Braumü ller H, Wieder T, Brenner E et al. (2013) T-helper-1-cell cytokines drive cancer into senescence. Nature 494:361-5
3. Bröcker EB, Echternacht-Happle K, Hamm H et al. (1987) Abnormal expression of class I and class II major histocompatibility antigens in alopecia areata: modulation by topical immunotherapy. J Invest Dermatol 88:564-8
4. Bronte V, Serafini P, Mazzoni A et al. (2003) L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 24:302-6
5. Clark RA, Chong B, Mirchandani N et al. (2006) The vast majority of CLA T cells are resident in normal skin. J Immunol 176:4431-9
6. Damian DL, Saw RP, Thompson JF (2014) Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. J Surg Oncol 109:308-13
7. Deng A, Chen S, Li Q et al. (2005) Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator. J Immunol 174:5243-8
8. Dudda JC, Perdue N, Bachtanian E et al. (2008) Foxp3 regulatory T cells maintain immune homeostasis in the skin. J Exp Med 205:1559-65
9. Freyschmidt E-J, Mathias CB, Diaz N et al. (2010) Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses. J Immunol 185:1295-302
10. Freyschmidt-Paul P, Happle R, McElwee KJ et al. (2003) Alopecia areata: treatment of today and tomorrow. J Investig Dermatol Symp Proc 8:12-7
11. Hoffmann R, Wenzel E, Huth A et al. (1994) Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol 103:530-3
12. Hunter N, Shaker O, Marei N (2011) Diphencyprone and topical tacrolimus as two topical immunotherapeutic modalities. Are they effective in the treatment of alopecia areata among Egyptian patients? A study using CD4, CD8 and MHC II as markers. J Dermatol Treat 22:2-10
13. Jiang H, Lin JJ, Su ZZ et al. (1995) Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 11:2477-86
14. Kroczek RA, Henn V (2012) The role of XCR1 and its ligand XCL1 in antigen cross-presentation by murine and human dendritic cells. Front Immunol 3:14
15. Lehtimäki S, Savinko T, Lahl K et al. (2012) The temporal and spatial dynamics of Foxp3 Treg cell-mediated suppression during contact hypersensitivity responses in a murine model. J Invest Dermatol 132:2744-51
16. Lei Y, Ripen AM, Ishimaru N et al. (2011) Aire-dependent production of XCL1 mediates medullary accumulation of thymic dendritic cells and contributes to regulatory T cell development. J Exp Med 208:383-94
17. Liu K, Nussenzweig MC (2010) Origin and development of dendritic cells. Immunol Rev 234:45-54
18. Ohlmeier MC, Traupe H, Luger TA et al. (2012) Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata-a large retrospective study on 142 patients with a self-controlled design. J Eur Acad Dermatol Venereol 26:503-7
19. Purwar R, Schlapbach C, Xiao S et al. (2012) Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 18:1248-53
20. Simonetti O, Lucarini G, Bernardini ML et al. (2004) Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study. Br J Dermatol 150:940-8
21. Stute J, Hausen BM, Schulz KH (1981) [Diphenylcyclopropenone-a new strong contact sensitizer (author's transl)]. Dermatosen Beruf Umw Occup Environ 29:12-4
22. Tomlinson GS, Cashmore TJ, Elkington PTG et al. (2011) Transcriptional profiling of innate and adaptive human immune responses to mycobacteria in the tuberculin skin test. Eur J Immunol 41:3253-60
23. Upitis JA, Krol A (2002) The use of diphenylcyclopropenone in the treatment of recalcitrant warts. J Cutan Med Surg 6:214-7
24. Vocanson M, Hennino A, Rozieres A et al. (2009) Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 64:1699-714
25. von Moos S, Johansen P, Waeckerle-Men Y et al. (2012) The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy. Allergy 67: 638-46